Key Highlights

  • On November 10, 2026, Acadia Pharmaceuticals (NASDAQ:ACAD) gained 10.79%, among the strongest performers of a session in which the S&P 500 slipped 0.38%.
  • The advance came after oral argument at the US Court of Appeals for the Federal Circuit concerning the Patent on the 34 mg capsule formulation of Nuplazid.
  • A ruling that upholds the patent keeps Nuplazid protected until February 2038, whereas a loss leaves protection ending in October 2030 through its compound patent and paediatric exclusivity.
  • A decision is anticipated in the first half of 2027, and remlifanserin data will be shown at a medical meeting on November 17.

Why Shares Moved

Late on November 9, Acadia Pharmaceuticals (NASDAQ:ACAD) offered comments on the oral argument in the appeal brought by generic drugmakers against a May 2025 district court judgment that upheld its Nuplazid formulation patent. Nuplazid is the only approved therapy for hallucinations and delusions tied to Parkinson's disease psychosis. Investors seem to have taken the hearing as favourable, and the stock rose 10.79% the following day. A lot rides on the outcome. Nuplazid makes up a major share of company revenue, and the gap between protection through 2030 and through 2038 means several more years of branded sales with no generic rivals. Management stressed that the court has set no timeline and that it expects a decision in the first half of 2027, so the rally reflects a revised view of the odds and not a final result. Questions from judges are an imperfect guide to rulings, and appeals courts can reverse or remand lower court decisions.

Fundamentals Behind the Shares

Third-quarter 2026 Revenue came to USD 342 million, a 22% rise from the prior year, powered by Nuplazid and by Daybue, the treatment for Rett syndrome. Acadia lifted its Daybue sales guidance to USD 505 million to USD 520 million and put total revenue guidance at USD 1.265 billion to USD 1.295 billion. The numbers describe two growing commercial products and enough Cash Flow to fund the pipeline. Policy is one headwind, since Nuplazid is expected to face a negotiated Medicare price under the Inflation Reduction Act from 2029, cutting Medicare revenue even ahead of any generic entry. That makes patent years after 2029 somewhat less valuable than they would otherwise be, though still meaningful for long-term forecasts and for how the shares are valued. With so much of the valuation tied to how long Nuplazid stays exclusive, a small shift in perceived patent risk can move the stock sharply.

Upcoming Catalysts

Another catalyst comes soon. On November 17, the company will present Phase 2 data from the RADIANT study of remlifanserin, which tested once-daily 60 mg and 30 mg doses against placebo, at a leading Alzheimer's disease conference in Boston. Remlifanserin targets psychosis in Alzheimer's disease, a far bigger population than Parkinson's disease psychosis, so good data would give Acadia a third growth driver. Canadian investors following this Nasdaq-listed stock through a domestic brokerage can treat the patent ruling, Daybue growth outside the US and remlifanserin progress as the three issues shaping valuation through 2027. For Acadia Pharmaceuticals (NASDAQ:ACAD), strong remlifanserin results would move the story from defending current revenue to building new growth, while weak results would leave the patent outcome carrying more weight.

Where Things Stand

Acadia gained 10.79% on November 10, 2026 after an appeals court heard arguments on the Nuplazid formulation patent, which would shield the drug until 2038 if upheld. A ruling is expected in the first half of 2027. Third-quarter revenue grew 22%, and remlifanserin data on November 17 add to the catalysts ahead.